BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 18033786)

  • 1. Variation in the mutation frequency determining quinolone resistance in Chlamydia trachomatis serovars L2 and D.
    Rupp J; Solbach W; Gieffers J
    J Antimicrob Chemother; 2008 Jan; 61(1):91-4. PubMed ID: 18033786
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Selection of quinolone resistance in Streptococcus pneumoniae exposed in vitro to subinhibitory drug concentrations.
    Avrain L; Garvey M; Mesaros N; Glupczynski Y; Mingeot-Leclercq MP; Piddock LJ; Tulkens PM; Vanhoof R; Van Bambeke F
    J Antimicrob Chemother; 2007 Nov; 60(5):965-72. PubMed ID: 17693451
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Emergence of high-level fluoroquinolone resistance in emm6 Streptococcus pyogenes and in vitro resistance selection with ciprofloxacin, levofloxacin and moxifloxacin.
    Malhotra-Kumar S; Van Heirstraeten L; Lammens C; Chapelle S; Goossens H
    J Antimicrob Chemother; 2009 May; 63(5):886-94. PubMed ID: 19279051
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Analysis of point mutations in the ygeD, gyrA and parC genes in fluoroquinolones resistant clinical isolates of Chlamydia trachomatis].
    Misiurina OIu; Shipitsina EV; Finashutina IuP; Lazarev VN; Akopian TA; Savicheva AM; Govorun VM
    Mol Gen Mikrobiol Virusol; 2004; (3):3-7. PubMed ID: 15354934
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Molecular mechanisms of decreased susceptibility to fluoroquinolones in avian Salmonella serovars and their mutants selected during the determination of mutant prevention concentrations.
    Kehrenberg C; de Jong A; Friederichs S; Cloeckaert A; Schwarz S
    J Antimicrob Chemother; 2007 May; 59(5):886-92. PubMed ID: 17369276
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Frequency of 1st- and 2nd-step topoisomerase mutations in Streptococcus pneumoniae following levofloxacin and moxifloxacin exposure.
    Hovde LB; Simonson DA; Rotschafer JC
    Diagn Microbiol Infect Dis; 2008 Mar; 60(3):295-9. PubMed ID: 18053674
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Diversity of moxifloxacin resistance during a nosocomial outbreak of a predominantly ribotype ARU 027 Clostridium difficile diarrhea.
    Carman RJ; Genheimer CW; Rafii F; Park M; Hiltonsmith MF; Lyerly DM
    Anaerobe; 2009 Dec; 15(6):244-8. PubMed ID: 19818865
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Frequencies and mechanisms of resistance to moxifloxacin in nosocomial isolates of Acinetobacter baumannii.
    Spence RP; Towner KJ
    J Antimicrob Chemother; 2003 Oct; 52(4):687-90. PubMed ID: 12951327
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Reduction of the fitness burden of quinolone resistance in Pseudomonas aeruginosa.
    Kugelberg E; Löfmark S; Wretlind B; Andersson DI
    J Antimicrob Chemother; 2005 Jan; 55(1):22-30. PubMed ID: 15574475
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In vitro development of resistance to DX-619 and other quinolones in enterococci.
    Wickman PA; Black JA; Smith Moland E; Thomson KS; Hanson ND
    J Antimicrob Chemother; 2006 Dec; 58(6):1268-73. PubMed ID: 17062613
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In vitro pharmacodynamics of moxifloxacin versus levofloxacin against 4 strains of Streptococcus pneumoniae: 1 wild type, 2 first-step parC mutants, and 1 pump mutant.
    Schafer J; Hovde LB; Simonson D; Rotschafer JC
    Diagn Microbiol Infect Dis; 2008 Feb; 60(2):155-61. PubMed ID: 17910998
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Emergence of resistant Streptococcus pneumoniae in an in vitro dynamic model that simulates moxifloxacin concentrations inside and outside the mutant selection window: related changes in susceptibility, resistance frequency and bacterial killing.
    Zinner SH; Lubenko IY; Gilbert D; Simmons K; Zhao X; Drlica K; Firsov AA
    J Antimicrob Chemother; 2003 Oct; 52(4):616-22. PubMed ID: 12951352
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of full gyrA, gyrB, parC and parE gene sequences between all Ureaplasma parvum and Ureaplasma urealyticum serovars to separate true fluoroquinolone antibiotic resistance mutations from non-resistance polymorphism.
    Beeton ML; Chalker VJ; Kotecha S; Spiller OB
    J Antimicrob Chemother; 2009 Sep; 64(3):529-38. PubMed ID: 19567408
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of bacterial kill when modelling the bronchopulmonary pharmacokinetic profile of moxifloxacin and levofloxacin against parC-containing isolates of Streptococcus pneumoniae.
    Deryke CA; Du X; Nicolau DP
    J Antimicrob Chemother; 2006 Sep; 58(3):601-9. PubMed ID: 16857688
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparative in vitro activity of PGE 9262932 and fluoroquinolones against Canadian clinical Streptococcus pneumoniae isolates, including molecularly characterized ciprofloxacin-resistant isolates.
    Adam HJ; Schurek KN; Decorby MR; Weshnoweski B; Vashisht R; Karlowsky K; Hoban DJ; Zhanel GG
    J Antimicrob Chemother; 2006 Jul; 58(1):202-4. PubMed ID: 16636082
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Low selection of topoisomerase mutants from strains of Escherichia coli harbouring plasmid-borne qnr genes.
    Cesaro A; Bettoni RR; Lascols C; Mérens A; Soussy CJ; Cambau E
    J Antimicrob Chemother; 2008 May; 61(5):1007-15. PubMed ID: 18325893
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dual-targeting properties of the 3-aminopyrrolidyl quinolones, DC-159a and sitafloxacin, against DNA gyrase and topoisomerase IV: contribution to reducing in vitro emergence of quinolone-resistant Streptococcus pneumoniae.
    Okumura R; Hirata T; Onodera Y; Hoshino K; Otani T; Yamamoto T
    J Antimicrob Chemother; 2008 Jul; 62(1):98-104. PubMed ID: 18390884
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacodynamics of moxifloxacin against a high inoculum of Escherichia coli in an in vitro infection model.
    Singh R; Ledesma KR; Chang KT; Hou JG; Prince RA; Tam VH
    J Antimicrob Chemother; 2009 Sep; 64(3):556-62. PubMed ID: 19589810
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Fluoroquinolone-resistant Brucella melitensis mutants obtained in vitro.
    Lázaro FG; Rodríguez-Tarazona RE; García-Rodríguez JA; Muñoz-Bellido JL
    Int J Antimicrob Agents; 2009 Sep; 34(3):252-4. PubMed ID: 19243922
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mutational paths towards increased fluoroquinolone resistance in Legionella pneumophila.
    Almahmoud I; Kay E; Schneider D; Maurin M
    J Antimicrob Chemother; 2009 Aug; 64(2):284-93. PubMed ID: 19474069
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.